ESSA Pharma Inc. Files Definitive Proxy Statement

TL;DR

ESSA Pharma filed its proxy statement, get ready for shareholder votes.

AI Summary

ESSA Pharma Inc. filed a Definitive Proxy Statement (DEFA14A) on August 14, 2025. This filing is related to the company's proxy materials, which are typically used for shareholder meetings to vote on corporate matters. The filing does not contain specific financial details or proposals but serves as the official record for the proxy statement.

Why It Matters

This filing indicates that ESSA Pharma Inc. is proceeding with corporate governance activities, likely involving shareholder votes on important company decisions.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not inherently present new financial or operational risks.

Key Players & Entities

• ESSA Pharma Inc. (company) — Registrant
• 0001104659-25-078741 (filing_id) — Accession Number
• 20250814 (date) — Filing Date

FAQ

Key Financial Figures

• $80,000,000 — stribution in the aggregate amount of US$80,000,000 (the " Distribution ") to the holders o
• $1.69 — Shareholders will receive approximately $1.69 per Common Share in the Distribution (s

Filing Documents

• tm2522137d6_defa14a.htm (DEFA14A) — 43KB
• tm2522137d6_ex99-1.htm (EX-99.1) — 18KB
• 0001104659-25-078741.txt ( ) — 62KB

01

Item 8.01 Other Events. On August 14, 2025, ESSA Pharma Inc. (the " Company ") issued a press release announcing that, in connection with the Company's recently announced return of capital distribution in the aggregate amount of US$80,000,000 (the " Distribution ") to the holders of common shares of the Company (" Common Shares " and the holders of such Common Shares, the " Shareholders ") as part of the discontinuance and winding-up of the business of the Company pursuant to the Company's previously announced transaction with XenoTherapeutics, Inc. (" Xeno "), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Common Shares (the " Transaction "), the Nasdaq Stock Market LLC (" Nasdaq ") has determined that the ex-dividend date for the Distribution will be August 25, 2025 (the " Ex-Dividend Date "), the first business day after the payment date. The Distribution is scheduled to be paid to Shareholders on August 22, 2025 and Shareholders will receive approximately $1.69 per Common Share in the Distribution (subject to applicable withholding). Because the Distribution represents more than 25% of the price of the Common Shares, Nasdaq has determined that the Common Shares will trade with "due bills" representing an assignment of the right to receive the Distribution during the period from August 19, 2025 through and including August 25, 2025 (the " Due Bill Period "). Thus, the Common Shares will trade with this "due bill" and the assignment of the right to receive the Distribution during the Due Bill Period until the Ex-Dividend Date. Shareholders who sell their Common Shares during the Due Bill Period will be selling their right to the Distribution, and such Shareholder will not be entitled to receive the Distribution (even if the trade will settle after the Due Bill Period). Persons who purchase Common Shares during the Due Bill Period will be entitled to receive the Distribution (even if the trade will settle af

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated August 14, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Forward Looking Statements

Forward Looking Statements This communication, and any related oral statements, contains certain information which, as presented, constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, " forward-looking statements "). Forward-looking statements include, but are not limited to, statements that relate to future events and often address expected future business and financial performance, containing words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions and include, but are not limited to, statements regarding the proposed timing and completion of the Transaction, the amounts payable under the Transaction; the timing and receipt of securityholder, regulatory and court approvals of the Transaction; the satisfaction of the conditions to the completion of the Transaction and other statements that are not statements of historical facts. In this communication, these forward-looking statements are based on the Company 's current expectations, estimates and projections regarding, among other things, the expected date of closing of the Transaction and the potential benefits thereof, its business and industry, management's beliefs and certain assumptions made by the Company, all of which are beyond the ability of the Company to control or predict, and which may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied thereby, including the consummation of the Transaction and the anticipated benefits thereof. Such statements reflect the Company's current views with r

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ESSA PHARMA INC. (Registrant) Date: August 14, 2025 By: /s/ David Wood Name: David Wood Title: Chief Financial Officer

View Full Filing

View this DEFA14A filing on SEC EDGAR